Kyowa Hakko Kirin Co.

Ōsaka, Japan

Kyowa Hakko Kirin Co.

Ōsaka, Japan
SEARCH FILTERS
Time filter
Source Type

Provided are: a preparation method for an aqueous solution that performs stable filtration in a short time and which has high versatility and improved membrane filtration; an aqueous solution prepared using the preparation method; a cell culturing method using the aqueous solution prepared using the preparation method; a production method for a physiologically active substance using the culturing method; the physiologically active substance produced using the aqueous solution production method; a method for membrane filtration of the aqueous solution prepared using the aqueous solution preparation method; a method for improving the membrane filtration of the aqueous solution; and a method for preparing the aqueous solution, membrane filtrating same, culturing cells using the aqueous solution, and producing the physiologically active substance. The present invention pertains to an aqueous solution preparation method characterized by the addition of a chelating agent.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-02-22

The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-02-15

An oligonucleotide having a nucleotide residue or a nucleoside residue represented by formula (I) {wherein X^(1) is an oxygen atom or the like, R^(1) is formula (IIA) (wherein R^(5A) is halogen or the like, and R^(6A) is a hydrogen atom or the like) , formula (IVA) (wherein Y^(3A) is a nitrogen atom or the like, and Y^(4A) is CH or the like), or the like, R^(2) is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R^(3) is a hydrogen atom or the like, or formula (VI)(wherein n2 is 1, 2 or 3)} at the 5 end thereof, wherein the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3, is provided.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-01-18

The present invention provides a nucleic acid having activity to suppress expression of IRF5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.


As a technique capable of culturing anchorage-dependent cells without using an anchorage, provided is a medium for anchorage-dependent cells, which comprises MFG-E8 (Milk fat globule-EGF factor 8) or a fragment of the protein. This medium can promote adhesion of anchorage-dependent cells in the absence of an anchorage, enables the survival and proliferation (colony formation) of the cells, and further, also enables the subsequent differentiation if the anchorage-dependent cells are stem cells.


According to the present invention, anti-death receptor 3 (DR3) antagonistic IgG antibodies and antibody fragments thereof, wherein the antibodies and the antibody fragments thereof display a decreased agonistic activity or no agonistic activity for DR3 through their binding, an antibody compositions and an antibody fragment compositions comprising them, a nucleotide sequence encoding the antibody or the antibody fragment, a vector comprising the nucleotide sequences, an amino acid sequences of the antibodies or the antibody fragments, a method of producing the antibodies or the antibody fragments thereof, and a method of decreasing the agonistic potency of an antibody against DR3 through its binding, are provided.


Patent
Pfizer and Kyowa Hakko Kirin Co. | Date: 2017-03-29

The present disclosure describes combination therapies comprising an antibody which specifically binds to human CCR4 and a selective 4-1BB agonist, and the use of the combination therapies for the treatment of cancer.


Patent
Kyowa Hakko Kirin Co. | Date: 2017-05-03

The present invention provides a cationic lipid represented by the formula (I)^(1) and R^(2) each represents alkyl having 8 to 24 carbon atoms or the like; R^(3) represents a hydrogen atom, alkyl having 1 to 3 carbon atoms, the formula (A)^(4) and R^(5) each represents a hydrogen atom or the like, and n^(3) represents an integer from 2 to 6, or the formula (B)^(6) and R^(7) each represents a hydrogen atom or the like, and n^(4) represents an integer from 1 to 6; n^(1) represents an integer from 0 to 4; and n^(2) represents an integer from 1 to 4, provided that the case where n^(1) is 0 and n^(2) is 1 is excluded, and a composition which contains the cationic lipid and a nucleic acid, or the like.


Patent
Kyowa Hakko Kirin Co. and Dicerna Pharmaceuticals | Date: 2017-04-12

The present invention provides a composition for suppressing the expression of the CKAP5 gene, the composition comprising a lipid particle containing a double-stranded nucleic acid as a drug and a cationic lipid,the double-stranded nucleic acid having an antisense strand having a base sequence complementary to the sequence of at least 19 continuous bases in CKAP5 gene mRNA of any one of SEQ ID NOs: 1 to 6,the cationic lipid being represented by formula (I):R^(1) and R^(2) are the same or different and are each linear or branched alkyl, alkenyl or alkynyl of 12 to 24 carbon atoms;L^(1) and L^(2) are the same or different and are each -CO-O- or -O-CO-;a and b are the same or different and are each 1 to 3; andR^(3) is a hydrogen atom, alkyl of 1 to 6 carbon atoms, or alkenyl of 3 to 6 carbon atoms;a medicament comprising the composition, and the like.


The invention provides a method for treating a cancer with a human FOLR1-targeting drug by increasing an expression of folate receptor (hereinafter abbreviated to FOLR1) by using an antagonist for folic acid metabolism, a medicament for a cancer containing a human FOLR1-targeting drug for increasing an expression of FOLR1 by using an antagonist for folic acid metabolism and a method for enhancing a therapeutic effect of a human FOLR1-targeting drug by increasing an expression of FOLR1 in a cancer cell by using an antagonist for folic acid metabolism. For example, the invention provides a more effective therapeutic method using an antagonist for folic acid metabolism with a human FOLR1-targeting drug, for cancer patients in which an expression level of FOLR1 is low and in which an anti-tumor activity of the human FOLR1-targeting drug is not exhibited sufficiently or for cancer patients in which a treatment of a cancer expressing FOLR1 is to be further enhanced.

Loading Kyowa Hakko Kirin Co. collaborators
Loading Kyowa Hakko Kirin Co. collaborators